Results 11 to 20 of about 118,257 (252)

Mass spectrometry captures off-target drug binding and provides mechanistic insights into the human metalloprotease ZMPSTE24. [PDF]

, 2016
Off-target binding of hydrophobic drugs can lead to unwanted side effects, either through specific or non-specific binding to unintended membrane protein targets.
Carpenter, Elisabeth P, Gault, Joseph, Marcoux, Julien, Mehmood, Shahid, Michaelis, Susan, Quigley, Andrew, Robinson, Carol V, Young, Stephen G   +7 more
core   +2 more sources

A modular system to evaluate the efficacy of protease inhibitors against HIV-2.

PLoS ONE, 2014
The human immunodeficiency virus (HIV) protease is a homodimeric aspartyl protease that is crucial for the viral life-cycle, cleaving proviral polyproteins, hence creating mature protein components that are required for the formation of an infectious ...
Mohamed Mahdi, Krisztina Matúz, Ferenc Tóth, József Tőzsér   +3 more
doaj   +1 more source

Rapid enzymatic test for phenotypic HIV protease drug resistance [PDF]

, 2003
A phenotypic resistance test based on recombinant expression of the active HIV protease in E. coli from patient blood samples was developed. The protease is purified in a rapid onestep procedure as active enzyme and tested for inhibition by five selected
Assfalg-Machleidt, Irmgard, Helm, K. von der, Hoffmann, D., Koszinowski, U., Machleidt, Werner, Nitschko, H.   +5 more
core   +1 more source

Probing the Pharmacological Binding Properties, and Reactivity of Selective Phytochemicals as Potential HIV-1 protease Inhibitors

Universitas Scientiarum, 2019
The HIV-1 protease plays an essential role in the replication cycle of HIV-1; therefore there is a direct need to develop novel inhibitors of the HIV-1 protease, which can cease the viral replication.
Ammara Akhtar, Waqar Hussain, Nouman Rasool3
doaj   +1 more source

HIV-1 Protease Inhibitors [PDF]

Clinical Infectious Diseases, 2000
Treatment of human immunodeficiency virus type 1 (HIV-1) infection with regimens that include protease inhibitors (PIs) has contributed to marked improvements in HIV-related disease progression and mortality. Five PIs are approved by the US Food and Drug Administration and have potent activity in vitro.
openaire   +2 more sources

Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study [PDF]

, 2014
Background: Atazanavir and lopinavir represent the main HIV protease inhibitors recommended in pregnancy, but comparative data in pregnant women are limited. Methods: Women from a national observational study, exposed in pregnancy to either atazanavir or
. . . ]., Anna Degli Antoni, Anna Maria Marconi, Arsenio Spinillo, CAPRETTI, MARIA GRAZIA, Carmela Pinnetti, Daniela Francisci, Enrica Tamburrini, FALDELLA, GIACOMO, Giulia Masuelli, Giuseppina Liuzzi, Marco Floridia, Marina Ravizza, MARSICO, CONCETTA, Marta Fiscon, on behalf of The Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy [. . ., Pasquale Martinelli, Vania Giacomet   +17 more
core   +1 more source

Proteochemometric modeling of HIV protease susceptibility

BMC Bioinformatics, 2008
Background A major obstacle in treatment of HIV is the ability of the virus to mutate rapidly into drug-resistant variants. A method for predicting the susceptibility of mutated HIV strains to antiviral agents would provide substantial clinical benefit ...
Prusis Peteris, Spjuth Ola, Eklund Martin, Lapins Maris, Wikberg Jarl ES   +4 more
doaj   +1 more source

The association between protease inhibitors and anal cancer outcomes in veterans living with HIV treated with definitive chemoradiation: a retrospective study

BMC Cancer, 2021
Background The incidence of anal squamous cell carcinoma has been increasing, particularly in people living with HIV (PLWH). There is concern that radiosensitizing drugs, such as protease inhibitors, commonly used in the management of HIV, may increase ...
Alison K. Yoder, David S. Lakomy, Yongquan Dong, Suchismita Raychaudhury, Kathryn Royse, Christine Hartman, Peter Richardson, Donna L. White, Jennifer R. Kramer, Lilie L. Lin, Elizabeth Chiao   +10 more
doaj   +1 more source

Accessory mutations balance the marginal stability of the HIV-1 protease in drug resistance

, 2020
The HIV-1 protease is a major target of inhibitor drugs in AIDS therapies. The therapies are impaired by mutations of the HIV-1 protease that can lead to resistance to protease inhibitors.
Hemmateenejad, B., Weikl, T.
core   +1 more source

Sechs historische Grabsteine, um 1700, vom Alten Friedhof in Gießen [PDF]

, 1994
In this work, we applied a coarse-grained molecular dynamics method for simulating inhibitors entering the binding cavity of human immunodeficiency virus type 1 protease (HIV-1 PR).
Huang, Yonggang, Hwang, K. C., Ji, Baohua, Li, Dechang, Liu, Ming S.   +4 more
core   +1 more source